AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01026350 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: colostrum enriched with anti flu antibodies
Description: each volunteer will receive six 1.2 g oral tablets (equivalent to 600 mg of bovine colostrum powder each) once a day for two weeks.
Study NCT00608881 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: coenzyme Q10
Description: 4 - 300 mg CoQ chewable wafers taken orally twice a day
Study NCT00608881 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: an inactive substance
Study NCT04202276 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: diet assessment
Description: Food frequency questionnaire to investigate differences in diet of children and adolescents with GERD compared to the age- and sex matched control group.
Study NCT03994601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986288
Description: Specified dose on specified days
Study NCT00761358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Z-338
Description: Oral
Study NCT00761358 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral
Study NCT01382095 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant fimbrial adhesin dscCfaE
Description: 50 ug on study days 0, 21 and 42
Study NCT01382095 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant fimbrial adhesin dscCfaE
Description: 250 ug on study days 0, 21 and 42
Study NCT01382095 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Modified E. coli heat labile enterotoxin LTR192G
Description: 50 ug on study days 0, 21 and 42
Study NCT04384211 — intervention group
Intervention type: OTHER
Intervention: Computer Assisted Detection Software For Vertebral Fractures
Description: A device named Smart Bone that is using CT image retrospectively acquired to entails a second review of CT images with Vertebral Compression Fractures through an interactive AI program developed by Quanta Computer Inc. was applied to the CT images. The device is a computer-aided detection (CADe) software application and is designed to assist radiologists to analyze Spine CT images. The device uses deep learning methods to perform vertebrae detection and classification of images.
Study NCT00709930 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic field generator
Description: dosage:Magnetic field generator Exposure to 1-μT 8/6-Hz ELF-EMF frequency:10min/day duration:1 month
Study NCT00709930 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo magnetic field generator
Description: Placebo device with no magnetic fields
Study NCT02369289 — intervention group
Intervention type: OTHER
Intervention: bone mineral density test
Study NCT02256254 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: 2 Simvastatin capsules of 20 mg every evening for 14 days
Study NCT02256254 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 placebo capsules every evening for 14 days
Study NCT01637246 — intervention group
Intervention type: DRUG
Intervention: Any Fixed Combination Therapy
Description: Patients with POAG or OHT previously treated with monotherapy and currently treated with any fixed combination therapy. This was a retrospective chart review study, so no treatment was administered in this study.
Study NCT03750968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carotenoid Group
Description: Softgel active ingredients: Lutein 10 mg and Zeaxanthin 2 mg in safflower oil
Study NCT03750968 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Placebo ingredients: Safflower oil
Study NCT03218306 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surgical Pleth Index
Description: Effector site concentration of remifentanil based on SPI
Study NCT03994601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study NCT03218306 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical guidance
Description: Effector site concentration of remifentanil based on hemodynamic data
Study NCT06371755 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Ultrasound examination with REMS technology
Description: The proposed study is defined as interventional because it introduces an ultrasound examination in the standard clinical routine. The diagnostic approach does not vary during the study and the prescription of any therapeutic treatment is performed on the basis of the conventional DXA diagnosis. This ultrasound examination does not involve additional risks for the patient with the benefit of not using ionizing radiation; it lasts only few minutes and can be performed without moving the patient from the same bed on which he is already positioned for DXA examination.
Study NCT01444183 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Progressive muscle relaxation
Description: Subjects practice a progressive muscle relaxation exercise for 15 minutes every AM and 5 minutes every PM~Both groups will practice twice daily, one 15 minute practice in the AM and a 5 minute practice in the PM. An additional 5 minute mid-day practice will occur only when e-diary entries from experience sampling meet specific predetermined criteria.
Study NCT01444183 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham exercise
Description: The focused attention practices will consist of one or more of the following components: movement of body parts, breathing exercises, and writing exercises.~Both groups will practice twice daily, one 15 minute practice in the AM and a 5 minute practice in the PM. An additional 5 minute mid-day practice will occur only when e-diary entries from experience sampling meet specific predetermined criteria.
Study NCT02914197 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Full information
Description: Patients will be randomized to receive full information or standard information at the study start. The second wave will follow the same randomization process 6 months following the study start.
Study NCT03594461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept Injection
Description: Intense Treatment Regimen for Refractory Neovascular Age-Related Macular Degeneration with or without Polypoidal Choroidal Vasculopathy
Study NCT03892525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selicrelumab
Description: escalated dose in intratumoral injection, every 3 weeks, for 3 cycles
Study NCT03892525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1200mg IV every 3 week until progression or relapse for maximum 1 year
Study NCT04061941 — intervention group
Intervention type: BEHAVIORAL
Intervention: Cognitive Assessment
Description: Assessment on cognitive dysfunction using standardised cognitive tests
Study NCT01230918 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 99mTc-NC100692
Description: HCM and ACS subjects: 99mTc-NC100692 SPECT scan, CMR and echocardiography images will be obtained and compared.~Normal control: 99mTc-NC100692 SPECT scan, CMR and echocardiography imaging obtained for comparison with HCM and ACS images.
Study NCT03379441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Injectable Product
Description: Pembrolizumab Injectable Product 200 mg Q3W Intravenous
Study NCT00838695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: Intravenous phenylephrine at low doses (approximately 10 doses ranging from 0-5000 ng/min) Intravenous nitroglycerin at low doses (approximately 10 doses ranging from 0.05-100 ng/min)
Study NCT00550823 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac CT 0BRILLIANT 64
Description: Cardiac CT
Study NCT04156204 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication Event Monitoring System (MEMS)
Description: AYA kidney recipients will receive a Medication Event Monitoring System (MEMS) via medication bottle and cap system
Study NCT04156204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Once-Daily Tacrolimus extended release
Description: AYA kidney recipients will receive once daily tacrolimus XR 1-10mg daily
Study NCT01156155 — intervention group
Intervention type: RADIATION
Intervention: Digital xray of jaw and teeth
Description: one time xray of jaw and teeth
Study NCT01156155 — intervention group
Intervention type: PROCEDURE
Intervention: Blood draw
Description: Three to four tablespoons of blood drawn.
Study NCT01156155 — intervention group
Intervention type: OTHER
Intervention: questionnaires
Description: completed questionnaires regarding patient's health and functional ability.
Study NCT01156155 — intervention group
Intervention type: PROCEDURE
Intervention: Periodontal Examination
Description: Periodontal examination including measurement of gum pockets with a probe. Bacterial samples taken.
Study NCT01156155 — intervention group
Intervention type: OTHER
Intervention: Bilateral digital xray of hands
Description: One time digital xray of hands
Study NCT03988842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alteplase
Description: Lyophilized powder for reconstitution in 50mg vials
Study NCT03988842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin
Description: Heparin sodium in 0.45% sodium chloride injection for intravenous use
Study NCT03988842 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Unfractionated heparin
Description: Heparin sodium in 0.45% sodium chloride injection for intravenous use
Study NCT03988842 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Saline solution reconstituted to mimic Alteplase 50mg vial
Study NCT03988842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: Apixaban tablet
Study NCT03988842 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban
Description: Apixaban tablet
Study NCT00308997 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: 1-hertz Repetitive Transcranial Magnetic Stimulation
Description: Sham stimulation given to Wernicke's area or a right homologous area for 16 minutes per day x 5 days for week I, the same for week II with switch from right to left or left to right, and 5 more stimulation sessions (16 minutes per session) to the side producing greater benefit for week III.
Study NCT00308997 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active 1-Hertz Repetitive transcranial magnetic stimulation
Description: Active stimulation given to Wernicke's area or a right homologous area for 16 minutes per day x 5 days for week I, the same for week II with switch from right to left or left to right, and 5 more stimulation sessions (16 minutes per session) to the side producing greater benefit for week III.
Study NCT00979121 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: Subjects received an initial 40mg loading dose followed by 20 mg of study drug daily by mouth or feeding tube for 28 days or until discharged from the study hospital.
Study NCT00979121 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects received placebo by mouth or feeding tube daily for 28 days or until discharged from study hospital.
Study NCT02891915 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Amoxicillin is an aminopenicillin antibiotic
Study NCT02891915 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin-clavulanate
Description: A fixed-ratio combination of amoxicillin trihydrate, an aminopenicillin, and potassium clavulanate, a beta-lactamase inhibitor, used to treat a broad-spectrum of bacterial infections, especially resistant strains.
Study NCT02891915 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefdinir
Description: Cefdinir is a cephalosporin antibiotic used to treat bacterial infections in many different parts of the body.
Study NCT02891915 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03778515 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: Observational Study of novel MR imaging and image processing techniques that will provide reliable and fully quantitative evaluation of inflammation, chronic structural changes and vascularity in patients with Ankylosing Spondylitis (AS).
Study NCT01289314 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TLH
Description: Total laparoscopic hysterectomy (TLH)
Study NCT01289314 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic supracervical hysterectomy
Description: Laparoscopic supracervical hysterectomy (LSH)
Study NCT01503918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valaciclovir/Aciclovir
Description: 2g valaciclovir, four times a day, enterally for 28 days, or until discharge from the critical care unit, but for a minimum of 14 days unless discharged from hospital. Those unable to receive enteral drugs will receive intravenous aciclovir 10mg/kg three times a day. Dosing modified in the presence of renal dysfunction.
Study NCT01503918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valganciclovir/Ganciclovir
Description: 450mg valganciclovir, once a day, by enteral route. Treatment will continue for 28 days, or until discharge from the critical care unit, but for a minimum of 14 days unless discharged from hospital. Intravenous ganciclovir 2.5mg/kg once a day will be used if drugs cannot be given enterally. Treatment dosing will be modified for renal dysfunction
Study NCT02578316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Study phase dosing: participants received an initial single dose of radiolabelled 14C-lenvatinib oral patient dosing solution containing 24 mg of lenvatinib as anhydrous free base and radioactivity of 3.7 millibecquerel (MBq) on Day 1.~Extension phase dosing: 24 mg of 14C-lenvatinib: 2 x 10mg, and 4 x 1mg or 1 x 4mg tablets once-daily, continuously in each 28-day cycle during extension phase.
Study NCT02901314 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: on-demand audio messages of heart failure education themes
Study NCT02706340 — intervention group
Intervention type: OTHER
Intervention: No intervention - observational study only
Study NCT02539719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC-003
Study NCT02539719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC-003 in combination with ABBV-181
Study NCT04585672 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Ammonia infusion
Description: Ammonia metabolism investigated in healthy individuals and patients with cirrhosis with and without ammonia lowering agent: glycerolphenylbutyrat (healthy) and Lactulose + Rifaximin (Cirrhosis)
Study NCT01115517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 1.25 mg/mL applied one time intraoperatively using bevacizumab-soaked filter paper manually applied to bare sclera during pterygium surgery for 2 minutes, followed by copious rinsing with balanced salt solution.
Study NCT01844440 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High resolution manometry
Description: Subjects will undergo impedance / manometry recording with solid-state catheter systems, during a 30-min fasting and a 2-hour postprandial periods.
Study NCT03268902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin Oral Liquid Product
Description: Azithromycin 20 mg/kg administered by study personnel at 6, 9, 12 and 15 months
Study NCT02137616 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: risperidone
Description: Risperdal tablets
Study NCT02137616 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olanzapine
Description: olanzapine tablets
Study NCT02137616 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine
Description: quetiapine tablets
Study NCT02137616 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Aripiprazole tablets
Study NCT02107261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: incobotulinumtoxin A
Description: Incobotulinumtoxin A is being used on average doses between 10U and 30 Units per subject, but at no time will any subject receive over 100 Units. Each study visit, the assessing physician will select the muscles and the amounts of medication to be injected.
Study NCT02107261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: matching placebo
Study NCT00709098 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: iloprost
Description: Iloprost 5 mcg delivered by I-neb(R) adaptive aerosol delivery (AAD)(R) System power disc-6 administered 6 to 9 times per day for 12 weeks. If patient enters open label follow-up period, iloprost 5 mcg delivered by I-neb(R)AAD(R) System power disc-15 administered 6 to 9 times per day until the end of study.
Study NCT00709098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iloprost
Description: Iloprost 5 mcg delivered by I-neb(R)AAD(R) System power disc-15 administered 6 to 9 times per day for 12 weeks. If patient enters open label follow-up period, iloprost 5 mcg delivered by I-neb(R)AAD(R) System power disc-15 administered 6 to 9 times per day until the end of study.
Study NCT00359658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisolon
Description: prednisolon withdrawal: reduction of maintenance dosage, 0,5 mg of the daily dose every week till withdrawal
Study NCT00359658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolatmofetile
Description: Mycophenolatmofetile administration: start doses 250 mg, increase of the daily dose about 250 mg every week till reaching 2 g/daily
Study NCT00359658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporin A
Description: Cyclosporin A reduction: 8 weeks after starting prednisolon withdrawal and Mycophenolatmofetile administration reduction of Cyclosporin A trough level till a range from 50 to 90 ng/ml
Study NCT02431273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDF IVR
Study NCT02431273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDF-FTC IVR
Study NCT02431273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDF-FTC-MVC IVR
Study NCT00868504 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT02269475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI3250
Description: MEDI3250
Study NCT02269475 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04877340 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: needle punction
Description: EUS-guided sampling of pancreatic solid lesions obtained with the 22-gauge
Study NCT04877340 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: needle punction
Description: EUS-guided sampling of pancreatic solid lesions obtained with the 22-gauge
Study NCT03074617 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LTE field
Description: electromagnetic field of the latest standard in mobile communication (long term evolution, LTE)
Study NCT03074617 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham field
Description: no electromagnetic field
Study NCT00558454 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Iron
Description: Ferrous succinate mixture
Study NCT00558454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron
Description: Ferrous succinate mixture
Study NCT02222493 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06438179
Description: PF-06438179 will be administered by intravenous infusion at an initial dose of 3 mg/kg at 0, 2 and 6 weeks, then every 8 weeks.
Study NCT02222493 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab
Description: Infliximab will be administered by intravenous infusion at an initial dose of 3 mg/kg at 0, 2 and 6 weeks, then every 8 weeks.
Study NCT00468156 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: written materials only
Description: related to fruit/vegetable servings/day
Study NCT00468156 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: written materials
Description: related to fruit/vegetable servings/day
Study NCT00468156 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: telephone support
Description: related to fruit/vegetable servings/day
Study NCT03563690 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: treatment1
Description: 1. Acupoints：Liangqiu（ST34）,Xuehai（SP10）,Neixiyan（EX-LE4）,Dubi(ST35),Yanglingquan (GB34)and Yinlingquan (SP9)~2. operation: the needles will be manipulated using techniques including lifting, thrusting, twisting, and rotating, until De Qi is achieved for 30 minutes.
Study NCT03563690 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: treatment2
Description: 1. Acupoints：Needling points are the same to the above group~2. operation: The electrode will be connected Neixiyan (EX-LE4) and Dubi (ST35) and electrode wire will be connected to the electro-acupuncture apparatus using dilatational wave with a frequency of 2/100 Hz, the current intensity is within participants'tolerance, for 30 minutes.